Trial Profile
A randomised study of 'bluelight' hexyl aminolevulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional 'whitelight' transurethral resection of newly diagnosed bladder tumours comparing rates of tumour recurrence over one year - a Phase IV trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2018
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary) ; Mitomycin
- Indications Bladder cancer
- Focus Therapeutic Use
- 05 Apr 2011 New trial record
- 22 Mar 2011 Results presented at the 26th Congress of the European Association of Urology.